keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimer antidepressants

keyword
https://www.readbyqxmd.com/read/29760188/depression-in-type-1-diabetes-was-associated-with-high-levels-of-circulating-galectin-3
#1
Eva O Melin, Jonatan Dereke, Maria Thunander, Magnus Hillman
OBJECTIVE: Neuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication, and cardiovascular complications. DESIGN: Cross-sectional. METHODS: Participants were T1D patients (n=283, 56% men, age 18-59 years, diabetes duration ≥1 year)...
May 14, 2018: Endocrine Connections
https://www.readbyqxmd.com/read/29753049/antidepressant-effects-of-creatine-on-amyloid-%C3%AE-1-40-treated-mice-the-role-of-gsk-3%C3%AE-nrf-2-pathway
#2
Julia M Rosa, Francis L Pazini, Mauricio P Cunha, André R S Colla, Luana M Manosso, Gianni Mancini, Ana Cristina G Souza, Andreza F de Bem, Rui Daniel Prediger, Ana Lúcia S Rodrigues
Alzheimer's disease (AD) is characterized by progressive synaptic dysfunction and neuronal lost in specific brain areas including hippocampus, resulting in memory/learning deficits and cognitive impairments. In addition, non-cognitive symptoms are reported in AD patients, such as anxiety, apathy and depressed mood. The current antidepressant drugs present reduced efficacy to improve depressive symptoms in AD patients. Here, we investigated the ability of creatine, a compound with neuroprotective and antidepressant properties, to counteract amyloid β1-40 peptide-induced depressive-like behavior in mice...
May 9, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29751080/prenylated-%C3%AE-diketones-two-new-additions-to-the-family-of-biologically-active-hypericum-perforatum-l-hypericaceae-secondary-metabolites
#3
Niko S Radulović, Marija S Genčić, Nikola M Stojanović, Pavle J Randjelović, Nicolas Baldovini, Vanya Kurteva
Two novel β-diketones, 2,6,9-trimethyl-8-decene-3,5-dione (A) and 3,7,10-trimethyl-9-undecene-4,6-dione (B), were identified from the renowned medicinal plant Hypericum perforatum L. The structures of β-diketones A and B were corroborated by syntheses (4 steps starting from methyl acetoacetate, overall yields 30% and 23%, respectively). In solution, these β-diketones predominantly exist as two rapidly interconverting β-keto-enol tautomers. The structures of A and B show some common fragments with the molecules of hyperforin and adhyperforin, respectively, the acknowledged multi-target secondary metabolites from St...
May 8, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29742912/the-impact-of-a-long-term-rivastigmine-and-donepezil-treatment-on-all-cause-mortality-in-patients-with-alzheimer-s-disease
#4
Jakub Kazmierski, Chaido Messini-Zachou, Mara Gkioka, Magda Tsolaki
Cholinesterase inhibitors (ChEIs) are the mainstays of symptomatic treatment of Alzheimer's disease (AD); however, their efficacy is limited, and their use was associated with deaths in some groups of patients. The aim of the current study was to assess the impact of the long-term use of ChEIs on mortality in patients with AD. This observational, longitudinal study included 1171 adult patients with a diagnosis of AD treated with donepezil or rivastigmine. Each patient was observed for 24 months or until death...
January 1, 2018: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/29736334/-sideritis-scardica-extracts-inhibit-aggregation-and-toxicity-of-amyloid-%C3%AE-in-caenorhabditis-elegans-used-as-a-model-for-alzheimer-s-disease
#5
Felix Heiner, Björn Feistel, Michael Wink
Background: Beyond its traditional uses in the Balkan area, Sideritis scardica (known as Greek mountain tea, Lamiaceae) is currently extensively investigated for its pharmacological activity in the central nervous system. Antidepressant, psychostimulating, cognition-enhancing and neuroprotective properties have been described. In this study, we tested hydroalcoholic extracts of S. scardica for their potential to counteract amyloid-β toxicity and aggregation, which plays a crucial role in the pathogenesis of Alzheimer's disease...
2018: PeerJ
https://www.readbyqxmd.com/read/29727467/pharmacological-interventions-for-apathy-in-alzheimer-s-disease
#6
REVIEW
Myuri T Ruthirakuhan, Nathan Herrmann, Eleenor H Abraham, Sarah Chan, Krista L Lanctôt
BACKGROUND: Despite the high prevalence of apathy in Alzheimer's disease (AD), and its harmful effects, there are currently no therapies proven to treat this symptom. Recently, a number of pharmacological therapies have been investigated as potential treatments for apathy in AD. OBJECTIVES: Objective 1: To assess the safety and efficacy of pharmacotherapies for the treatment of apathy in Alzheimer's disease (AD).Objective 2: To assess the effect on apathy of pharmacotherapies investigated for other primary outcomes in the treatment of AD...
May 4, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29726758/pharmacotherapy-for-the-treatment-of-depression-in-patients-with-alzheimer-s-disease-a-treatment-resistant-depressive-disorder
#7
Madia Lozupone, Maddalena La Montagna, Francesca D'Urso, Carla Piccininni, Rodolfo Sardone, Vittorio Dibello, Gianluigi Giannelli, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Nicola Quaranta, Davide Seripa, Antonello Bellomo, Giancarlo Logroscino, Francesco Panza
Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. Areas covered: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs)...
May 4, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29707086/epigenetics-of-metabolic-syndrome-as-a-mood-disorder
#8
REVIEW
Sermin Kesebir
Mood disorders comprise major depressive disorder (MDD), bipolar disorder (BD) and the milder forms of these two disorders. Reccurring MDD is also known as unipolar disorder. The distinction between unipolar and bipolar disorders was first suggested in 1957 by Leonard and was made official after support by several studies in 1980. Indeed, in 150 AD, Aretaeus of Cappadocia wrote "It seems to me that melancholia is the beginning and a part of mania". Additionally, Kraepelin, who proposed the first medical disease model in psychiatry a century ago, considered recurrent unipolar depression cases under the category of bipolar disorder and conceptualized spectrum disorders...
June 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29705602/liraglutide-attenuates-the-depressive-and-anxiety-like-behaviour-in-the-corticosterone-induced-depression-model-via-improving-hippocampal-neural-plasticity
#9
Han Weina, Niu Yuhu, Holscher Christian, Li Birong, Shen Feiyu, Wang Le
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk factor of psychiatric diseases. This relationship opens the opportunity to develop new antidepressant drugs by repurposing antidiabetic drugs. Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. In addition, the GLP-1 analog liraglutide has been shown to promote neurogenesis, which is seen to play important roles in memory formation and cognitive and emotional processing...
April 26, 2018: Brain Research
https://www.readbyqxmd.com/read/29696800/oxoisoaporphine-alkaloids-prospective-anti-alzheimer-s-anticancer-and-antidepression-agents
#10
Jiayao Zhang, Li Chen, Jianbo Sun
Oxoisoaporphine alkaloids are a family of oxoisoquinoline-derived alkaloids that have been firstly isolated from the rhizome of Menispermum dauricum DC. (Menispermaceae). It was demonstrated in some research that oxoisoaporphine alkaloids possess various biological properties, such as cholinesterase and β-amyloid (Aβ) inhibitory, acting as topoisomerase intercalator, monoamine oxidase A (MAO-A) inhibitory , etc, which are expected to become anti-Alzheimer's, anticancer and antidepression drugs. This review provides an overview on natural sources, synthetic route, bioactivities, structure-function relationship and modification investigation of oxoisoaporphine alkaloids, aiming to provide references of the structure-activity relationships for designing and development of oxoisoaporphine derivatives with higher efficacy and therapeutic potential...
April 25, 2018: ChemMedChem
https://www.readbyqxmd.com/read/29656013/escitalopram-alleviates-stress-induced-alzheimer-s-disease-like-tau-pathologies-and-cognitive-deficits-by-reducing-hypothalamic-pituitary-adrenal-axis-reactivity-and-insulin-gsk-3%C3%AE-signal-pathway-activity
#11
Chao Wu, Wei-Gang Gong, Yan-Juan Wang, Jun-Jun Sun, Hong Zhou, Zhi-Jun Zhang, Qing-Guo Ren
Chronic stress, a causal factor for depression, can also cause cognitive impairments and tau pathology. However, whether and how the selective serotonin reuptake inhibitor antidepressant escitalopram ameliorates these effects are still unclear. In the present study, rats were subjected to chronic mild unpredictable stress for 8 weeks. Following the initial 4 weeks, the stressed animals were separated into susceptible (depressive) and unsusceptible (resistant) groups based on behavioral tests. Then, escitalopram (10 mg/kg i...
July 2018: Neurobiology of Aging
https://www.readbyqxmd.com/read/29619930/neurological-and-psychiatric-comorbidity-in-patients-with-heart-failure-risk-and-prognosis
#12
Kasper Adelborg
Heart failure is a complex clinical syndrome and one of the leading causes of morbidity and mortality with a prevalence of 1%-2% of the adult population. The prognosis is poor with a 5-year mortality rate of 50%, which partly can be attributed to the presence of concomitant comorbidity, including neurological and psychiatric comorbidities. However, the prognostic impact of depression and the role of heart failure as a risk factor for dementia and stroke are not fully understood.
 Denmark is well-known for its unique health registries...
April 2018: Danish Medical Journal
https://www.readbyqxmd.com/read/29619929/depression-stroke-and-dementia-in-patients-with-myocardial-infarction
#13
Jens Sundbøll
The connection between the heart and mind has been studied since Sir William Harvey observed more than 350 years ago that negative emotions adversely affect the heart. Today, we know that diseases of the mind can affect the heart and, conversely, that heart diseases can cause both physical and mental diseases of the brain. To explore this relation further, we examined how previous depression affects survival in patients with myocardial infarction (MI) (study II), and how the occurrence of MI affects the risk of ischemic and hemorrhagic stroke (study III) and dementia (study IV)...
April 2018: Danish Medical Journal
https://www.readbyqxmd.com/read/29611482/potential-use-of-nanomedicine-for-the-anti-inflammatory-treatment-of-neurodegenerative-diseases
#14
Maria Dolores Cayero-Otero, Ana M Espinosa-Oliva, Antonio J Herrera, Irene Garcia-Dominguez, Mercedes Fernandez-Arevalo, Lucia Martin-Banderas, Rocio M de Pablos
Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the scientific community faces the challenge of getting the drugs used in these treatments to cross the blood-brain barrier (BBB) and reach the brain in sufficient concentration to be able to exert its effect. Hence, researchers across multiple disciplines are working together in order to improve the ability of therapeutics to penetrate the BBB...
April 2, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29551658/the-role-of-memantine-in-the-treatment-of-major-depressive-disorder-clinical-efficacy-and-mechanisms-of-action
#15
REVIEW
Meysam Amidfar, Gislaine Z Réus, Joao Quevedo, Yong-Ku Kim
A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects...
May 15, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29516165/kinetics-mechanism-and-inhibition-of-monoamine-oxidase
#16
REVIEW
Rona R Ramsay, Alen Albreht
Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs. While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design. In neurodegenerative diseases, MAO inhibitors can help to maintain neurotransmitter levels, making it a common feature in novel multi-target combinations designed to combat Alzheimer's disease, albeit not yet proven clinically...
March 7, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29438781/neurobiological-links-between-depression-and-ad-the-role-of-tgf-%C3%AE-1-signaling-as-a-new-pharmacological-target
#17
REVIEW
Filippo Caraci, Simona Federica Spampinato, Maria Grazia Morgese, Fabio Tascedda, Maria Grazia Salluzzo, Maria Concetta Giambirtone, Giuseppe Caruso, Antonio Munafò, Sebastiano Alfio Torrisi, Gian Marco Leggio, Luigia Trabace, Ferdinando Nicoletti, Filippo Drago, Maria Angela Sortino, Agata Copani
In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling...
April 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29374303/negative-allosteric-modulation-of-alpha-5-containing-gaba-a-receptors-engenders-antidepressant-like-effects-and-selectively-prevents-age-associated-hyperactivity-in-tau-depositing-mice
#18
Nina Z Xu, Margot Ernst, Marco Treven, Rok Cerne, Mark Wakulchik, Xia Li, Timothy M Jones, Scott D Gleason, Denise Morrow, Jeffrey M Schkeryantz, Md Toufiqur Rahman, Guanguan Li, Michael M Poe, James M Cook, Jeffrey M Witkin
RATIONALE: Associated with frank neuropathology, patients with Alzheimer's disease suffer from a host of neuropsychiatric symptoms that include depression, apathy, agitation, and aggression. Negative allosteric modulators (NAMs) of α5-containing GABAA receptors have been suggested to be a novel target for antidepressant action. We hypothesized that pharmacological modulation of this target would engender increased motivation in stressful environments. METHODS: We utilized electrophysiological recordings from Xenopus oocytes and behavioral measures in mice to address this hypothesis...
April 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29350177/antidepressant-medication-in-a-german-cohort-of-patients-with-alzheimer-s-disease
#19
Philipp Hessmann, Richard Dodel, Erika Baum, Matthias J Müller, Greta Paschke, Bernhard Kis, Jan Zeidler, Mike Klora, Jens-Peter Reese, Monika Balzer-Geldsetzer
OBJECTIVE: The use of antidepressant drugs in dementia patients is associated with the risk of adverse events, and the evidence for relevant effects is scarce. We aimed to determine the associations between the prescription of antidepressants and patients' sociodemographic (e.g., age, gender, living situation) and clinical characteristics (e.g., disease severity, neuropsychiatric symptoms). MATERIALS AND METHODS: We included 395 institutionalized and community-dwelling patients with Alzheimer's disease (AD) across all severity stages of dementia in a cross-sectional study design...
March 2018: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29332554/evaluating-the-dose-dependent-mechanism-of-action-of-trazodone-by-estimation-of-occupancies-for-different-brain-neurotransmitter-targets
#20
Luca Settimo, David Taylor
Trazodone is a drug that was introduced in the clinic almost 40 years ago. It is licensed to treat depression, but it is also commonly used off-label to treat insomnia. A recent study shows that it could be promising in preventing neurodegeneration in mice, and clinical trials to assess its possible beneficial effects on dementia and Alzheimer's disease are expected to start soon in humans. In this study, we describe the dose-dependent pharmacology of trazodone by carrying out pharmacokinetic simulations aiming to predict the brain concentrations of trazodone for different drug-dosing regimens and calculating occupancy for 28 different targets for which published trazodone-binding data are available...
January 2018: Journal of Psychopharmacology
keyword
keyword
53641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"